U.S. market Closed. Opens in 4 hours 25 minutes

KYMR | Kymera Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 40.14 - 41.71
52 Week Range 22.35 - 53.27
Beta 2.41
Implied Volatility 66.80%
IV Rank 63.11%
Day's Volume 107,146
Average Volume 436,161
Shares Outstanding 64,765,300
Market Cap 2,643,719,546
Sector Healthcare
Industry Biotechnology
IPO Date 2020-08-21
Valuation
Profitability
Growth
Health
P/E Ratio -17.44
Forward P/E Ratio N/A
EPS -2.34
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 184
Country USA
Website KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
*Chart delayed
Analyzing fundamentals for KYMR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is passable. For more detailed analysis please see KYMR Fundamentals page.

Watching at KYMR technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on KYMR Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙